SABS Stock — SAB Biotherapeutics Inc

SAB Biotherapeutics Inc (SABS)

Updated October 16, 2026.

SABS is a Stock. Total return is -97.5% over the past 5.7 years, 208.7 points behind SPY at 111.2%.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies to treat immune system disorders and infectious diseases, with its lead candidate SAB-142 in Phase 2b trials for autoimmune type 1 diabetes. The company does not currently distribute income to shareholders. This stock appeals primarily to investors with a high risk tolerance seeking exposure to early-stage biopharmaceutical development rather than current income.

SABS performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.5% over the past 5.7 years, 208.7 points behind SPY at 111.2%. Over the past year its total return — price change plus distributions reinvested — is 16.6%. Its deepest 1-year drawdown was 45.8%.

SABS key facts

Asset type

Stock

Asset class

Equity

Inception date

02/09/2021

Distribution frequency

None

Last close

$2.53 (as of 2026-10-16)

Market cap

$230,195,511

Average volume

756767.0

Beta

0.584

Payout ratio

0.0%

EPS

$-1.19

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SABS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 45.8%.

Who may consider SABS — and who may not

It is a weaker fit for investors who need monthly cash flow (SABS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SABS

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions